The modern use of hydroxyurea for children with sickle cell anemia
Over the past 40 years, the introduction and refinement of hydroxyurea therapy has led to remarkable progress for the care of individuals with sickle cell anemia (SCA). From initial small proof-of-principle studies to multi-center Phase 3 controlled clinical trials and then numerous open-label stud...
Saved in:
| Main Authors: | Charles T. Quinn, Russell E. Ware |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia
by: Paul George, et al.
Published: (2025-07-01) -
Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities
by: Teresa Smith Latham, et al.
Published: (2025-05-01) -
Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01) -
Optimization of hydroxyurea in sickle cell disease in Brazil
by: Clarisse Lobo, et al.
Published: (2025-04-01) -
Efficacy of Hydroxyurea in Patients With Sickle Cell Anemia in a Low-Income Country (Côte d’Ivoire)
by: Kouassi Gustave Koffi, et al.
Published: (2025-01-01)